For instance, the MEK-MAPK-ERK pathway inhibitor PD184352 has been proven to significantly reduce the proliferation and steroidogenesis of the H295R adrenal cortical carcinoma cell line, providing valuable insights into new therapeutic approaches (32). The gene discussed is MAPK1; the disease is adrenal cortex carcinoma.